Context Therapeutics Inc
contexttherapeutics.comWhat Do They Do?
Develops T cell-engaging bispecific antibodies for solid tumors.
10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 23, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$14.6MView ↗
- ▲ +65% (Loss)
- vs −$8.8M in Q2 FY2025
-
Jul 31, 2026
Nasdaq notified Context of a minimum bid-price deficiency
The company had until January 25, 2027 to regain compliance before possible further review and delisting.
Sources
8-K, filed Jul 31, 2026
The Notification Letter provides an initial 180 calendar day period, or until January 25, 2027, in which to regain compliance, pursuant to…View ↗
-
Jun 15, 2026
CTIM-76 interim trial results showed confirmed responses in ovarian cancer
Two of seven evaluable patients had confirmed partial responses; the response rate was 29%.
Sources
8-K, filed Jun 15, 2026
On June 15, 2026, the Company issued a press release announcing positive interim efficacy and safety results from its ongoing Phase 1…View ↗
-
May 18, 2026
BioAtla amendment removed future royalties and milestone payments for CT-202
The license became irrevocable, royalty-free, fully paid-up and non-terminable.
Sources
8-K, filed May 18, 2026
On May 14, 2026 (the “Amendment Date”), Context Therapeutics Inc. (the “Company”) entered into a First Amendment (the “Amendment”) to that…View ↗
Portfolio focus
The earlier report paired its bispecific-antibody program with a progesterone-receptor program for female cancers; the latest report describes T cell-engaging candidates for solid tumors.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our…View ↗
Who Do They Compete With?
Competes with Beigene, Third Arc Bio, Xencor, Daiichi Sankyo, BioNTech, TORL, Amgen, RemeGen Biosciences, Outpace Bio, Navrogen, Bicycle Therapeutics, Pfizer, Eli Lilly, Corbus Pharmaceuticals, Bio-Thera, Mabwell, Adcentrx, Aktis Oncology, and Shanghai Henlius Biotech
10-K for FY2025, filed Mar 23, 2026For CTIM-76, our CLDN6 x CD3 TCE, we are aware of several companies developing T cell engagers against CLDN6. Several TCE candidates are…View ↗
Loading...
